Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23530875 | 0.86 | GAA (0.75) | GAACYP1A2KDM4EPOLBMAPK1 | |
| SCHEMBL101291 | 0.86 | GAA (1.00) | GAACYP1A2KDM4EPOLBMAPK1 | |
| SCHEMBL29469301 | 0.84 | GAA (0.52) | GAACYP1A2KDM4ERAB9ANPC1 | |
| SCHEMBL118187 | 0.83 | GAA (0.75) | GAACYP1A2KDM4EPOLBMAPK1 | |
| SCHEMBL12119842 | 0.83 | GAA (0.75) | GAACYP1A2KDM4EPOLBMAPK1 | |
| SCHEMBL7274660 | 0.83 | GAA (0.75) | GAACYP1A2KDM4EPOLBMAPK1 | |
| SCHEMBL3033258 | 0.83 | GAA (0.75) | GAACYP1A2KDM4EPOLBMAPK1 | |
| SCHEMBL118407 | 0.82 | GAA (0.73) | GAACYP1A2KDM4EPOLBMAPK1 | |
| SCHEMBL25262974 | 0.82 | GAA (0.73) | GAACYP1A2KDM4EPOLBMAPK1 | |
| SCHEMBL8608783 | 0.81 | GAA (0.71) | GAACYP1A2KDM4EPOLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473303-B2 | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino methyl]piperidin-3-ol compounds and their therapeutic use | Carrick Therapeutics Limited (IE) | 2025-11-18 | — | — | US | disclosed |
| CN-114929708-B | 4- [ [ (7-Aminopyrazolo [1,5-a ] pyrimidin-5-yl) amino ] methyl ] piperidin-3-ol compounds and their therapeutic uses | 卡里克治疗有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-11780837-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780837-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| CN-111892592-B | JAK kinase inhibitors and uses thereof | 江苏柯菲平医药股份有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-111320624-B | Triazolopyridine and imidazopyridine compounds, and preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2023-05-12 | — | — | CN | disclosed |
| US-20230144197-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2023-05-11 | — | — | US | disclosed |
| US-20230144197-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2023-05-11 | — | — | US | disclosed |
| US-20230144197-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2023-05-11 | — | — | US | disclosed |
| US-20220274983-A1 | JAK KINASE INHIBITOR AND USE THEREOF | JIANGSU CAREPHAR PHARMACEUTICAL CO., LTD. (CN) | 2022-09-01 | — | — | US | disclosed |
| US-20120277237-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2012-11-01 | — | — | US | disclosed |
| EP-2426115-A2 | Alkynyl derivatives as modulators of metabotropic glutamate receptors | Addex Pharma SA (CH) | 2012-03-07 | — | — | EP | disclosed |
| US-8101637-B2 | Alkynyl derivatives as modulators of metatropic glutamate receptors | ADDEX PHARMA SA (CH) | 2012-01-24 | — | — | US | disclosed |
| US-20100099695-A1 | HCV NS3 Protease Inhibitors | MSD ITALIA S.R.L. (IT) | 2010-04-22 | — | — | US | disclosed |
| US-20090124625-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2009-05-14 | — | — | US | disclosed |
| EP-1765795-A2 | ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharmaceuticals SA (CH) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005123703-A2 | ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2005-12-29 | — | — | WO | disclosed |
| US-5977385-A | VIRICIDES | SARAWAK MEDICHEM PHARMACEUTICALS (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0436831-A2 | Imidazo[1,2-a]pyridinylalkyl compounds for treatment of neurotoxic injury | G.D. Searle & Co. (US) | 1991-07-17 | — | — | EP | disclosed |
| WO-1991008211-A1 | IMIDAZO[1,2-a]PYRIDINYLALKYL COMPOUNDS FOR TREATMENT OF NEUROTOXIC INJURY | G.D. SEARLE & CO. (US) | 1991-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099695-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | GAA 429/4885CYP1A2 232/4885KDM4E 2747/4885 |
| US-20090124625-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | GAA 2249/4885CYP1A2 3019/4885KDM4E 1986/4885 |
| US-20220274983-A1 | JAK KINASE INHIBITOR AND USE THEREOF | JAK1, JAK2, JAK3 | GAA 2246/4885CYP1A2 1613/4885KDM4E 956/4885 |
| US-11780837-B2 | CXCR4 inhibitors and uses thereof | CXCR4, CXCL12, CXCR3 | GAA 3881/4885CYP1A2 4098/4885KDM4E 3366/4885 |
| US-20120277237-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | GAA 2330/4885CYP1A2 3599/4885KDM4E 1750/4885 |
| US-20230144197-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | CDK1, CDK3, CDK2 | GAA 2363/4885CYP1A2 3707/4885KDM4E 1443/4885 |
| US-12473303-B2 | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino methyl]piperidin-3-ol compounds and their therapeutic use | CDK3, CDK1, CDK2 | GAA 2284/4885CYP1A2 3691/4885KDM4E 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.